Navigation Links
United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
Date:7/28/2011

$

104,894$

96,3678.8%Tyvaso

61,80929,483109.6%Adcirca

16,8438,58996.1%Other

205282(27.3)%Total net revenues

$

183,751$

134,72136.4%Revenues for the quarter ended June 30, 2011 increased by $49.0 million, compared to the quarter ended June 30, 2010. The growth in revenues primarily reflects the increase in the number of patients being prescribed our products.

Expenses

The table below summarizes research and development expense by major project and non-project components (dollars in thousands):Three Months EndedJune 30,20112010Percentage ChangeProject and non-project component:Cardiopulmonary

$

24,490$

18,61931.5%Share-based compensation

(9,555)1,420(772.9)%Other

9,3058,5488.9%Total research and development expense

$

24,240$

28,587(15.2)%Cardiopulmonary. The increase in expenses related to our cardiopulmonary projects for the quarter ended June 30, 2011 was attributable largely to increases in expenses related to our FREEDOM-C2 and FREEDOM-M clinical trials and our development of beraprost-MR.

Share-based compensation. The decrease in share-based compensation for the quarter ended June 30, 2011, compared to the same quarter in 2010, corresponded to a reduction in share-based compensation recognized in connection with our share tracking awards plans as a result of the decrease in our stock price.

The table below summarizes selling, general and administrative expense by major categories (in thousands):Three Months EndedJune 30,20112010Percentage ChangeCategory:General and administrative

$

24,268$

18,75429.4%Sales and marketing

17,07212,90032.3%Share-based compensation

(17,484)(2,000)(774.2)%Total selling, general and administrative expense

$

23,856$

29,654(19.6)%General and administrative. The increase in general and administr
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
2. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
3. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
4. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
5. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
6. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
7. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
8. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
9. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
10. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
11. Report Details How States Respond to Citizens United Decision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that the ... and Mexico currently faces ... approved agents, the anticipated label extension of Boehringer ... of emerging biologics will substantially increase the competitiveness ... IL-5 inhibitors will introduce a new dynamic to the ...
(Date:8/21/2014)... Calif. , Aug. 21, 2014  Four-dimensional ... and behaviors based on external stimuli such as ... to have a disruptive effect in multiple industries.  ... the business landscape by printing objects ranging from ... and automotive sectors. Logo - ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... has been recognized as one of the nation’s ... 5000 magazine for the 2nd consecutive year. Inc. ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... , ... ... ... ...
... ... ... ... ...
... , ... ... ... , ...
Cached Biology Technology:YM sees nimotuzumab license unaffected by civil claim against licensor 2YM sees nimotuzumab license unaffected by civil claim against licensor 3YM sees nimotuzumab license unaffected by civil claim against licensor 4YM sees nimotuzumab license unaffected by civil claim against licensor 5Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 2Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 3Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 4Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 5Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 6InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 2InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 3InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 4InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 5InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 6InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 7
(Date:8/21/2014)... improving the food intake, health and quality of life ... three projects at the University of Waterloo receiving close ... of Health Research (CIHR). , Professor Heather Keller, ... and a Schlegel research chair in nutrition and aging, ... many Canadians living in long-term care homes are poorly ...
(Date:8/21/2014)... finding that has implications for life in other extreme ... solar system, LSU Associate Professor of Biological Sciences Brent ... Foundation, or NSF, this week published a paper confirming ... lies 800 meters (2600 feet) beneath the surface of ... Given that more than 400 subglacial lakes and numerous ...
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4Water window imaging opportunity 2
... New species are not just discovered in exotic localeseven ... new plants and animals. Academy scientists recently named a ... of fishes distantly related to sharks, from the coast ... species, the Eastern Pacific black ghostshark ( Hydrolagus melanophasma ...
... , , SEATTLE, Sept. ... leading provider of specialized reference laboratory and contract research services, today ... Terry M. Giles, providing for a $4 million loan (the "Loan") ... the Loan, on August 31, 2009, the Company also repurchased 2,391,906 ...
... , NEW YORK, Sept. 8 ... in its catalogue. , , ... http://www.reportlinker.com/p0131250/Carbon-Dioxide-Monitors.html , , This report ... of US$ by the following segments: End-tidal Carbon Dioxide (EtCO2) ...
Cached Biology News:New species of ghostshark from California and Baja California 2Pacific Biometrics Completes $4 Million Debt Financing 2Pacific Biometrics Completes $4 Million Debt Financing 3Pacific Biometrics Completes $4 Million Debt Financing 4Pacific Biometrics Completes $4 Million Debt Financing 5Reportlinker Adds Carbon Dioxide Monitors Report 2Reportlinker Adds Carbon Dioxide Monitors Report 3Reportlinker Adds Carbon Dioxide Monitors Report 4Reportlinker Adds Carbon Dioxide Monitors Report 5Reportlinker Adds Carbon Dioxide Monitors Report 6Reportlinker Adds Carbon Dioxide Monitors Report 7Reportlinker Adds Carbon Dioxide Monitors Report 8Reportlinker Adds Carbon Dioxide Monitors Report 9
... set the standard for sample concentration and drying. ... chamber uses a combination of centrifugal force, heat ... single run. , SC210A comes equipped with:, ... lasting chemical compatibility ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
... Jouan RC Standard MB (For small quantities ... biology samples) of vacuum concentrator/centrifugal evaporator systems ... and biochemistry for rapid and safe concentration ... be expanded with pumps, different of cold ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Biology Products: